Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 -0.42%78 Buyback Yield % is 0.00 as of Aug. 15, 2026. GuruFocus rates SHSE:603387 with a GF Score™ of 78/100 and a GF Value™ of ¥7.52 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 344 Medical Devices & Instruments companies, Getein Biotech ranks worse than 290697.38% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Getein Biotech's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Getein Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Getein Biotech's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a Buyback Yield % of 0.00 as of Aug. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Getein Biotech and its competitors. According to the industry distribution chart, Getein Biotech ranks #999999 out of 344 companies in the Medical Devices & Instruments industry.
Is Getein Biotech's Buyback Yield % too high?
Getein Biotech's current Buyback Yield % is 0.00. Based on the distribution chart, Getein Biotech ranks #999999 out of 344 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Getein Biotech has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #999999 out of 344 companies for Buyback Yield %. This places Getein Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Getein Biotech and its competitors. Getein Biotech's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.52, compared to a current price of ¥9.39 — trading 24.9% above its estimated fair value. The current Buyback Yield % is 0.00. Getein Biotech's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Buyback Yield % is 0.00 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥9.39 is trading 24.9% above its estimated GF Value™ of ¥7.52.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
Buyback Yield %: 0.00
GF Value™: ¥7.52 vs. price of ¥9.39 (24.9% above fair value)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
78GF Score
Get the complete analysis for SHSE:603387
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
